Publication number: 20100273816
Abstract: Disclosed are quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, W, W1, W2, W3, A, Ra, Ra?, Rb, Rb?, Rc, Rd, Rd?, Re, Rf, Rg, Rh, Ri Rj, Rk, Rm, Rn, Ro, Rp, Rq, and n, can be, independently, as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
Type:
Application
Filed:
May 15, 2008
Publication date:
October 28, 2010
Inventors:
Ronald Charles Bernotas, John William Ullrich, Jeremy Mark Travins, Jay Edward Wrobel, Rayomand Jal Unwalla
Publication number: 20100184786
Abstract: Disclosed are polar quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which, R1, R2, R3, R4, R5, R6, R22, R23, R24, R25, R26, R27, R28, R29, W, W1, W2, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, and n can be as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
Type:
Application
Filed:
November 19, 2009
Publication date:
July 22, 2010
Applicant:
Wyeth LLC
Inventors:
Jeremy Mark Travins, Ronald Charles Bernotas, Jay Edward Wrobel, David Harry Kaufman, Baihua Hu, James Winfield Jetter, David John O'Neill, Charles William Mann
Patent number: RE42353
Abstract: The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group sele
Type:
Grant
Filed:
September 23, 1997
Date of Patent:
May 10, 2011
Assignee:
AstraZeneca UK Limited
Inventors:
Andrew Peter Thomas, Craig Johnstone, Edward Clayton, Elaine Sophie Elizabeth Stokes, Jean-Jacques Marcel Lohmann, Laurent Francois Andre Hennequin